Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.
Marizoe Actives S.L. is a holding company located in Madrid, Spain. It has shares and other holdings in various nutraceutical companies in Europe and the US. With the new total shares of 30 349 371 in Eevia Health, Marizoe Actives will be holding 5,01% of the company's outstanding shares and votes when the new shares have been registered with Finnish authorities. Registration is expected this week.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Eevia Health Plc, ("Eevia" or "The Company"), has received sales order from Taiwan of c. 13 KEUR for an organically certified bilberry extract.
Eevia Health Plc ("Eevia" or "The Company") by the CEO Stein Ulve will present at the event "Stora Aktiedagarna" in Stockholm, which is arranged between March 13th and March 15th 2023 by Aktiespararna.
Eevia Health Plc ("Eevia" or "The Company") has received a 20 KEUR sales order for Feno-Chaga® Organic from a health-food customer in Finland.
Eevia Health Plc ("Eevia" or "The Company") has received a 12 KEUR sales order for Feno-Chaga® M from a health-food customer in Finland.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the fourth quarter of 2022.
Eevia Health Plc, ("Eevia" or "The Company"), has been certified by OK Kosher, US.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Matleena Kotila as the new Commercial manager. At the same time, Tommi Kilpeläinen's contract as Scientific Product Manager was discontinued in the trial period.
Eevia Health Plc ("Eevia" or "The Company") has received a positive decision from Business Finland for a business development grant of 243 840 EUR. The grant is a 50% financing of a total project budget of 487.680 EUR. The project has two work packages.
Eevia Health Plc ("Eevia" or "The Company") has received a 12 KEUR sales order for a Chaga extract from its US distributor Barrington Nutritionals.